Remove Compounding Remove Drug Development Remove Pharmaceutical Manufacturing
article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Defossilization of pharmaceutical manufacturing.

article thumbnail

Q&A with Mrunal Jaywant: How the Discovery of Nitrosamines in Medicines Shifted the Pharmaceutical Manufacturing Landscape

Quality Matters

FDA: The FDA provided recommended AIs for over 260 NDSRIs based on predicted carcinogenic potency categorization and four NDSRIs based on compound-specific data or read-across analysis from a surrogate and recommended interim AI limits for two NDSRIs, N-nitroso-duloxetine (600 ng/day) and N-nitroso-ciprofloxacin (12,000 ng/day).

article thumbnail

From pills to pollution: Need for eco-pharmacovigilance to safeguard environmental sustainability

Express Pharma

Pathways of pharmaceutical pollution Pharmaceuticals enter the environment through several main routes, each exacerbating the growing issue of contamination in our water, soil, and air.